What’s New

Home What’s New

24

Mar2016

Ontario’s CED Will No Longer Routinely Evaluate CDR- or pCODR-Reviewed Drug Products

Effective April 1, 2016, all drug products reviewed by the Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review ... Read More

15

Mar2016

Ontario Public Drug Programs Funds INFLECTRA™ (infliximab)

The Ontario Public Drug Programs (OPDP) began funding INFLECTRA™ (infliximab) as a Limited Use (LU) benefit for eligible ODB recipients, ... Read More

15

Mar2016

CADTH Call for Patient Input for INFLECTRA™ (Subsequent Entry Biologic)

The Canadian Agency for Drugs and Technologies in Health (CADTH) posted a call for patient input on  March 11, ... Read More

10

Mar2016

CADTH Call for Patient Input for Etanercept SEB

The Canadian Agency for Drugs and Technologies in Health (CADTH) posted a call for patient input on March 9, ... Read More